These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 35959373)

  • 1. ABCD3 is a prognostic biomarker for glioma and associated with immune infiltration: A study based on oncolysis of gliomas.
    Li J; Zhang Y; Qu Z; Ding R; Yin X
    Front Cell Infect Microbiol; 2022; 12():956801. PubMed ID: 35959373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deciphering the role of QPCTL in glioma progression and cancer immunotherapy.
    Liu Y; Lu S; Sun Y; Wang F; Yu S; Chen X; Wu LL; Yang H; Shi Y; Zhao K
    Front Immunol; 2023; 14():1166377. PubMed ID: 37063864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MCM10 as a novel prognostic biomarker and its relevance to immune infiltration in gliomas.
    Tian QS; Zhang Q; Huang W
    Technol Health Care; 2023; 31(4):1301-1317. PubMed ID: 36872806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
    Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
    Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
    Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
    Front Immunol; 2022; 13():899710. PubMed ID: 35677036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
    Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
    Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PLEKHA4 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Glioma.
    Zhang W; Li L; Bian PP; Luo QP; Xiong ZT
    Biomed Res Int; 2023; 2023():4504474. PubMed ID: 36714030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
    Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
    BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Single-cell transcriptome analysis of multigrade glioma heterogeneity and immune microenvironment revealed potential prognostic biomarkers].
    Liu J; Xu K; Ma L; Wang Y
    Sheng Wu Gong Cheng Xue Bao; 2022 Oct; 38(10):3790-3808. PubMed ID: 36305410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
    Zhao S; Li Y; Xu J; Shen L
    Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EFNA1 is a potential key gene that correlates with immune infiltration in low-grade glioma.
    Hao YP; Wang WY; Qiao Q; Li G
    Medicine (Baltimore); 2021 Jun; 100(22):e26188. PubMed ID: 34087884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel pyroptosis-related gene signature predicts the prognosis of glioma through immune infiltration.
    Zhang M; Cheng Y; Xue Z; Sun Q; Zhang J
    BMC Cancer; 2021 Dec; 21(1):1311. PubMed ID: 34876094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and validation of a risk signature based on extracellular matrix-related genes in gliomas.
    Liu J; Li G
    Medicine (Baltimore); 2021 Apr; 100(16):e25603. PubMed ID: 33879726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel prognostic biomarker TBC1D1 is associated with immunotherapy resistance in gliomas.
    Song D; Yang Q; Li L; Wei Y; Zhang C; Du H; Ren G; Li H
    Front Immunol; 2024; 15():1372113. PubMed ID: 38529286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ECM2, a prognostic biomarker for lower grade glioma, serves as a potential novel target for immunotherapy.
    Cheng X; Liu Z; Liang W; Zhu Q; Wang C; Wang H; Zhang J; Li P; Gao Y
    Int J Biochem Cell Biol; 2023 May; 158():106409. PubMed ID: 36997057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of beta-2 microglobulin expression on the survival of glioma patients via modulating the tumor immune microenvironment.
    Tang F; Zhao YH; Zhang Q; Wei W; Tian SF; Li C; Yao J; Wang ZF; Li ZQ
    CNS Neurosci Ther; 2021 Aug; 27(8):951-962. PubMed ID: 33960680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas.
    Zhao WJ; Ou GY; Lin WW
    Front Immunol; 2021; 12():682415. PubMed ID: 34054873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selenoprotein GPX1 is a prognostic and chemotherapy-related biomarker for brain lower grade glioma.
    Chen X; Fu G; Li L; Zhao Q; Ke Z; Zhang R
    J Trace Elem Med Biol; 2022 Dec; 74():127082. PubMed ID: 36155420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PTPRN Serves as a Prognostic Biomarker and Correlated with Immune Infiltrates in Low Grade Glioma.
    Li P; Chen F; Yao C; Zhu K; Zhang B; Zheng Z
    Brain Sci; 2022 Jun; 12(6):. PubMed ID: 35741647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive analysis of m
    Zhao K; Li W; Yang Y; Hu X; Dai Y; Huang M; Luo J; Zhang K; Zhao N
    Front Immunol; 2022; 13():955848. PubMed ID: 36203569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.